Annual report pursuant to Section 13 and 15(d)

Nature of Business (Tables)

v2.4.0.6
Nature of Business (Tables)
12 Months Ended
Dec. 31, 2012
Nature Of Business [Abstract]  
Schedule of Dispositions
During the three years ended December 31, 2012, we sold the following properties (in thousands):
Disposition Date
Property
Type
Gain on Sale
August 31, 2012
1700 Research Boulevard
Office
$
3,724

December 20, 2012
Plumtree Medical Center
Medical Office
1,400

 
 
Total 2012
$
5,124

 
 
 
 
April 5, 2011
Dulles Station, Phase I
Office
$

Various (1)
Industrial Portfolio (1)
Office/Industrial
97,491

 
 
Total 2011
$
97,491

 
 
 
 
June 18, 2010
Parklawn Portfolio(2)
Office/Industrial
$
7,942

December 21, 2010
The Ridges
Office
4,441

December 22, 2010
Ammendale I&II/Amvax
Industrial
9,216

 
 
Total 2010
$
21,599

(1) 
The Industrial Portfolio consists of every property in our industrial segment and two office properties (the Crescent and Albemarle Point), and we closed on the sale on three separate dates. On September 2, 2011, we closed on the sale of the two office properties (the Crescent and Albemarle Point) and 8880 Gorman Road, Dulles South IV, Fullerton Business Center, Hampton Overlook, Alban Business Center, Pickett Industrial Park, Northern Virginia Industrial Park I, 270 Technology Park, Fullerton Industrial Center, Sully Square, 9950 Business Parkway, Hampton South and 8900 Telegraph Road. On October 3, 2011, we closed the sale of Northern Virginia Industrial Park II. On November 1, 2011, we closed on the sale of 6100 Columbia Park Road and Dulles Business Park I and II.

(2) 
The Parklawn Portfolio consists of three office properties (Parklawn Plaza, Lexington Building and Saratoga Building) and one industrial property (Charleston Business Center).
We sold or classified as held for sale the following properties during the three years ended December 31, 2012:
Disposition Date
 
Property
 
Type
 
Rentable
Square Feet
(unaudited)
 
Contract
Sales Price
(in thousands)
 
Gain on Sale
(in thousands)
August 31, 2012
 
1700 Research Boulevard
 
Office
 
101,000

 
$
14,250

 
$
3,724

December 20, 2012
 
Plumtree Medical Center
 
Medical Office
 
33,000

 
8,750

 
1,400

N/A - Held for Sale
 
Atrium Building
 
Office
 
79,000

 
N/A

 
N/A

 
 
 
 
Total 2012
 
213,000

 
$
23,000

 
$
5,124

 
 
 
 
 
 
 
 
 
 
 
Various (1)
 
Industrial Portfolio (1)
 
Industrial/Office
 
3,092,000

 
$
350,900

 
$
97,491

April 5, 2011
 
Dulles Station, Phase I
 
Office
 
180,000

 
58,800

 

 
 
 
 
Total 2011
 
3,272,000

 
$
409,700

 
$
97,491

 
 
 
 
 
 
 
 
 
 
 
June 18, 2010
 
Parklawn Portfolio (2)
 
Office/Industrial
 
229,000

 
$
23,430

 
$
7,942

December 21, 2010
 
The Ridges
 
Office
 
104,000

 
27,500

 
4,441

December 22, 2010
 
Ammendale I&II and Amvax
 
Industrial
 
305,000

 
23,000

 
9,216

 
 
 
 
Total 2010
 
638,000

 
$
73,930

 
$
21,599

 
(1) 
The Industrial Portfolio consists of every property in our industrial segment and two office properties (the Crescent and Albemarle Point), and we closed on the sale on three separate dates. On September 2, 2011, we closed on the sale of the two office properties (the Crescent and Albemarle Point) and 8880 Gorman Road, Dulles South IV, Fullerton Business Center, Hampton Overlook, Alban Business Center, Pickett Industrial Park, Northern Virginia Industrial Park I, 270 Technology Park, Fullerton Industrial Center, Sully Square, 9950 Business Parkway, Hampton South and 8900 Telegraph Road. On October 3, 2011, we closed the sale of Northern Virginia Industrial Park II. On November 1, 2011, we closed on the sale of 6100 Columbia Park Road and Dulles Business Park I and II.
(2) 
The Parklawn Portfolio consists of three office properties (Parklawn Plaza, Lexington Building and Saratoga Building) and one industrial property (Charleston Business Center).
Taxable Percentage of Dividends Paid
The following is a breakdown of the taxable percentage of our dividends for the years ended December 31, 2012, 2011 and 2010,(unaudited):
 
2012
 
2011
 
2010
Ordinary income
72
%
 
60
%
 
55
%
Return of capital
26
%
 
17
%
 
31
%
Qualified dividends
%
 
5
%
 
%
Unrecaptured Section 1250 gain
2
%
 
13
%
 
11
%
Capital gain
%
 
5
%
 
3
%